Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 170261, 14 pages
http://dx.doi.org/10.1155/2013/170261
Research Article

Cyclohexylmethyl Flavonoids Suppress Propagation of Breast Cancer Stem Cells via Downregulation of NANOG

1Stem Cell Program, Genomics Research Center, Academia Sinica, Nangang, Taipei 115, Taiwan
2Graduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung 402, Taiwan
3Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan
4Asia-Pacific Ocean Research Center, National Sun Yat-sen University, Kaohsiung 804, Taiwan
5Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei 112, Taiwan
6Bioresource Collection and Research Center, Food Industry Research and Development Institute, Hsinchu 300, Taiwan
7The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University, Taichung 402, Taiwan
8Graduate Institute of Clinical Medicine, Taipei Medical University, Sinyi District, Taipei 110, Taiwan

Received 7 February 2013; Accepted 2 March 2013

Academic Editor: Hui-Fen Liao

Copyright © 2013 Wen-Ying Liao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Amir, O. C. Freedman, B. Seruga, and D. G. Evans, “Assessing women at high risk of breast cancer: a review of risk assessment models,” Journal of Natinoal Cancer Institue, vol. 102, no. 10, pp. 680–691, 2010. View at Publisher · View at Google Scholar
  2. M. A. Velasco-Velázquez, V. M. Popov, M. P. Lisanti, and R. G. Pestell, “The role of breast cancer stem cells in metastasis and therapeutic implication,” The American Journal of Pathology, vol. 179, no. 1, pp. 2–11, 2011. View at Publisher · View at Google Scholar
  3. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, and M. F. Clarke, “Prospective identification of tumorigenic breast cancer cells,” Proceedings of the National Academy of Sciences, vol. 100, no. 7, pp. 3983–2988, 2003. View at Publisher · View at Google Scholar
  4. R. Liu, X. Wang, G. Y. Chen et al., “The prognostic role of a gene signature from tumorigenic breast-cancer cells,” The New England Journal of Medicine, vol. 356, no. 3, pp. 217–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. J. E. Dick, “Breast cancer stem cells revealed,” Proceedings of the National Academy of Sciences, vol. 100, no. 7, pp. 3547–3549, 2003. View at Publisher · View at Google Scholar
  6. L. Patrawala, T. Calhoun, R. Schneider-Broussard, J. Zhou, K. Claypool, and D. G. Tang, “Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2 cancer cells are similarly tumorigenic,” Cancer Research, vol. 65, no. 14, pp. 6207–6219, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. X. Li, M. T. Lewis, J. Huang et al., “Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy,” Journal of the National Cancer Institute, vol. 100, no. 9, pp. 672–679, 2008. View at Publisher · View at Google Scholar
  8. F, Al-Ejeh, C. E. Smart et al., “Breast cancer stem cells: treatment resistance and therapeutic opportunities,” Carcinogenesis, vol. 32, no. 5, pp. 650–658, 2011. View at Publisher · View at Google Scholar
  9. S. Liu and M. S. Wicha, “Targeting breast cancer stem cells,” Journal of Clinical Oncology, vol. 28, no. 25, pp. 4006–4012, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. A. Beachy, S. S. Karhadkar, and D. M. Berman, “Tissue repair and stem cell renewal in carcinogenesis,” Nature, vol. 432, no. 7015, pp. 324–331, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. G. V. Glinsky, “Stemness genomics law governs clinical behavior of human cancer: implications for decision making in disease management,” Journal of Clinical Oncology, vol. 26, no. 17, pp. 2846–2853, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Ben-Porath, M. W. Thomson, V. J. Carey et al., “An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors,” Nature Genetics, vol. 40, no. 5, pp. 499–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Zhang, X. Wang, M. Li et al., “NANOGP8 is a retrogene expressed in cancers,” FEBS Journal, vol. 273, no. 8, pp. 1723–1730, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Ambady, C. Malcuit, O. Kashpur et al., “Expression of NANOG and NANOGP8 in a variety of undifferentiated and differentiated human cells,” The International of Developmental Biology, vol. 54, pp. 1743–1754, 2010. View at Publisher · View at Google Scholar
  15. C. R. Jeter, M. Badeaux, G. Choy et al., “Functional evidence that the self-renewal gene NANOG regulates human tumor development,” Stem Cells, vol. 27, no. 5, pp. 993–1005, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. C. R. Jeter, B. Liu, X. Liu et al., “NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation,” Oncogene, vol. 30, no. 36, pp. 3833–3845, 2011. View at Publisher · View at Google Scholar
  17. J. Han, F. Zhang, M. Yu et al., “RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells,” Cancer Letters, vol. 321, no. 1, pp. 80–88, 2012. View at Publisher · View at Google Scholar
  18. L. Y. W. Bourguignon, K. Peyrollier, W. Xia, and E. Gilad, “Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells,” Journal of Biological Chemistry, vol. 283, no. 25, pp. 17635–17651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. I. Cohen, M. Tagliaferri, and D. Tripathy, “Traditional Chinese medicine in the treatment of breast cancer,” Seminars in Oncology, vol. 29, no. 6, pp. 563–574, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. He, X. Zheng, C. Sit et al., “Using association rules mining to explore pattern of Chinese medicinal formulae (prescription) in treating and preventing breast cancer recurrence and metastasis,” Journal of Translational Medicine, vol. 10, supplement 1, article S12, 2012. View at Publisher · View at Google Scholar
  21. Y. C. Huang, T. L. Hwang, C. S. Chang et al., “Anti-inflammatory flavonoids from the rhizomes of Helminthostachys zeylanica,” Journal of Natural Products, vol. 72, no. 7, pp. 1273–1278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. C. Huang, T. L. Hwang, Y. L. Yang et al., “Acetogenin and prenylated flavonoids from helminthostachys zeylanica with inhibitory activity on superoxide generation and elastase release by neutrophils,” Planta Medica, vol. 76, no. 5, pp. 447–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Suja, P. G. Latha, P. Pushpangadan, and S. Rajasekharan, “Evaluation of hepatoprotective effects of Helminthostachys zeylanica (L.) Hook against carbon tetrachloride-induced liver damage in Wistar rats,” Journal of Ethnopharmacology, vol. 92, no. 1, pp. 61–66, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Singh, Z. A. Ali, S. T. H. Zaidi, and M. K. Siddqui, Fitoterapia, Department of Botany, Aligarh Muslim Universities, Aligarh, India, 1996.
  25. J. Jalil, A. A. Bidin, and T. S. Chye, “Phytochemical study of ophyoglosaceae family species,” in Proceedings of the Malays Biochemistry Society Conference, vol. 12, pp. 160–164, Fakultas Sains Hayati Universitas Kebangsaan, Bangi, Malaysia, 1986.
  26. J. Yu, M. A. Vodyanik, K. Smuga-Otto et al., “Induced pluripotent stem cell lines derived from human somatic cells,” Science, vol. 318, no. 5858, pp. 1917–1920, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. S. D. Boyd, K. Y. Tsai, and T. Jacks, “An intact HDM2 RING-finger domain is required for nuclear exclusion of p53,” Nature Cell Biology, vol. 2, no. 9, pp. 563–568, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. S. N. Tang, C. Singh, D. Nall, D. Meeker, S. Shankar, and R. K. Srivastava, “The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition,” Journal of Molecular Signaling, vol. 5, article no. 14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Sansone, G. Storci, S. Tavolari et al., “IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland,” Journal of Clinical Investigation, vol. 117, no. 12, pp. 3988–4002, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Lin, C. Chao, S. Saito et al., “p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression,” Nature Cell Biology, vol. 7, no. 2, pp. 165–171, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. I. Chambers, D. Colby, M. Robertson et al., “Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells,” Cell, vol. 113, no. 5, pp. 643–655, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Zhang, X. Wang, M. Li et al., “NANOGP8 is a retrogene expressed in cancers,” FEBS Journal, vol. 273, no. 8, pp. 1723–1730, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Susanto, Y. H. Lin, Y. N. Chen et al., “Porphyrin homeostasis maintained by ABCG2 regulates self-renewal of embryonic stem cells,” PLoS One, vol. 3, no. 12, Article ID e4023, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Takao, T. Yokota, and H. Koide, “β-Catenin up-regulates Nanog expression through interaction with Oct-3/4 in embryonic stem cells,” Biochemical and Biophysical Research Communications, vol. 353, no. 3, pp. 699–705, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Ginestier, E. Charafe-Jauffret, and D. Birnbaum, “p53 and cancer stem cells: the mevalonate connexion,” Cell Cycle, vol. 11, no. 14, pp. 2583–2584, 2012. View at Publisher · View at Google Scholar
  36. V. V. Prabhu, J. E. Allen, B. Hong, S. Zhang, H. Cheng, and W. S. El-Deiry, “Therapeutic targeting of the p53 pathway in cancer stem cells,” Expert Opinion on Therapeutic Targets, vol. 16, no. 12, pp. 1161–1174, 2012. View at Publisher · View at Google Scholar
  37. A. K. Bakkestuen and L. L. Gundersen, “Synthesis of (+)-trixagol and its enantiomer, the terpenoid side chain of (-)-agelasine E,” Tetrahedron, vol. 59, no. 1, pp. 115–121, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. C. Shen, S. Y. Cheng, Y. H. Kuo, T. L. Hwang, M. Y. Chiang, and A. T. Khalil, “Chemical transformation and biological activities of ambrein, a major product of ambergris from Physeter macrocephalus (Sperm Whale),” Journal of Natural Products, vol. 70, no. 2, pp. 147–153, 2007. View at Publisher · View at Google Scholar · View at Scopus